Jeffrey W. Albers Sells 15,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) Director Jeffrey W. Albers sold 15,000 shares of the firm's stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the sale, the director now directly owns 157,557 shares in the company, valued at $14,143,891.89. This represents a 8.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Blueprint Medicines Stock Up 1.4 %

Shares of BPMC stock traded up $1.21 during trading hours on Friday, reaching $90.14. The company had a trading volume of 1,267,436 shares, compared to its average volume of 690,807. The company has a market capitalization of $5.73 billion, a P/E ratio of -42.72 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. Blueprint Medicines Co. has a twelve month low of $72.24 and a twelve month high of $121.90. The stock's fifty day simple moving average is $92.45 and its 200 day simple moving average is $97.23.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same quarter last year, the company earned ($2.20) earnings per share. Blueprint Medicines's revenue for the quarter was up 126.5% on a year-over-year basis. As a group, sell-side analysts expect that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BPMC. JPMorgan Chase & Co. assumed coverage on shares of Blueprint Medicines in a research report on Thursday, November 14th. They set an "overweight" rating and a $126.00 target price on the stock. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, November 8th. Wells Fargo & Company dropped their target price on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research note on Thursday, October 31st. Wedbush reissued an "outperform" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Thursday, November 14th. Finally, Needham & Company LLC restated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $122.11.

Hedge Funds Weigh In On Blueprint Medicines

A number of institutional investors have recently added to or reduced their stakes in BPMC. Hsbc Holdings PLC purchased a new stake in shares of Blueprint Medicines during the second quarter worth about $1,060,000. Federated Hermes Inc. raised its position in shares of Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company's stock valued at $6,721,000 after purchasing an additional 13,579 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Blueprint Medicines by 48.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company's stock valued at $23,332,000 after buying an additional 82,693 shares during the last quarter. Nicholas Investment Partners LP acquired a new stake in shares of Blueprint Medicines during the second quarter worth approximately $4,377,000. Finally, Entropy Technologies LP bought a new stake in shares of Blueprint Medicines in the third quarter worth $999,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.